현실 세계 Where-Where- 언제? 메모리 테스트

Executive Industry Relevance

Episodic memory assessment is critical for early detection of cognitive decline in neurodegenerative and psychiatric disorders, yet traditional verbal tests lack ecological validity and spatial-temporal context. The Real-World What-Where-When memory test addresses this gap by enabling objective measurement of integrated object-location-occasion recall in a naturalistic setting. This supports target validation and mechanistic de-risking in CNS drug discovery by providing a translationally relevant, low-cost biomarker for episodic memory function.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses by dissociating object, spatial, and temporal memory components to clarify mechanistic contributions to episodic deficits.
• Operational Value: Provides a behaviorally grounded, ecologically valid readout for target engagement in preclinical models of cognitive aging and depression.

Screening & Assay Development

• Scientific Value: Generates quantitative, multi-dimensional output (what-where-when binding accuracy) suitable for hit-to-lead progression in cognitive enhancer screening.
• Operational Value: Requires no specialized equipment, enabling high-throughput, decentralized testing across sites with minimal training.

Translational & Preclinical Research

• Scientific Value: Bridges rodent what-where-when paradigms to human cognition, supporting cross-species target validation and predictive confidence in disease-relevant systems.
• Operational Value: Facilitates longitudinal tracking of cognitive trajectories in at-risk populations, improving risk-adjusted advancement decisions.

Pipeline & Workflow Integration

The test fits within the discovery continuum from target validation through lead identification to preclinical efficacy, offering a continuous, translationally aligned measure of episodic memory integrity.

• Discovery Biology: Supports hypothesis testing by isolating binding deficits from unimodal memory impairments, clarifying mechanism of action for pro-cognitive compounds.
• Screening: Delivers reproducible, quantitative recall accuracy metrics that enable compound comparison and structure-activity relationship analysis.
• Analytics: Provides component-level data (object, spatial, temporal) and binding scores, allowing mechanistic stratification of cognitive phenotypes.
• Translational Research: Aligns with preclinical episodic memory tasks, enhancing continuity from discovery to IND-enabling studies.
• Enterprise Reuse: Reusable across therapeutic areas (neurodegeneration, depression, schizophrenia) as a standardized cognitive endpoint.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence by reducing reliance on artificial verbal tasks and capturing real-world episodic memory processes.
• Operational Value: Ensures standardization and scalability through simple procedural instructions and minimal resource requirements.
• Strategic Value: Improves go/no-go decisions by detecting subtle, ecologically valid cognitive effects missed by conventional assays.
• Portfolio Impact: Enables risk-adjusted prioritization of compounds based on meaningful episodic memory improvement rather than isolated task performance.

Implementation Considerations

• Requires training in standardized object hiding and recall procedures to minimize administrator bias.
• Dependent on consistent environmental setup (cluttered room, object set, timing intervals) for cross-site reliability.
• Necessitates cross-team agreement on scoring criteria for what-where-when combinations versus component scores.
• Adaptation considerations include object familiarity and cultural relevance across diverse participant populations.
• Practical limitation: Susceptible to proactive interference if multiple test sessions are conducted in close succession without sufficient washout.

Biopharma FAQs